In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insulin Delivery: Still Waiting to Exhale

Executive Summary

After the commercial failure of Exubera, is inhaled insulin dead? Not at all. Exubera failed for very specific reasons: a cumbersome device, non-standard dosing, and no real clinical utility. The Exubera snafu has eroded the commercial value of inhaled insulin, but Nektar may be the best-positioned company currently competing in the inhaled insulin space. Nektar can afford to re-partner its version for less, because Pfizer has already paid for the bulk of the drug development work.
Advertisement

Related Content

Diabetes Device Market: Innovation Highlights Road to Growth
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2008
Can Oral GLP-1 Be More than Just Convenient?
Inhaled Insulin is Dead. Long Live Inhaled Insulin
Business and Technology Briefs
Pharma's New Follow-On Strategy
Exubera's Problem: It's Still Just Insulin
Inhaled Insulin: Being First Isn't Necessarily Best
Pfizer's Exubera: Breathing New Life Into Inhaled Insulin

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel